Extensive preclinical data support that blocking the TIM-3 signaling pathway may promote immune cells to mediate anti-tumor responses, and can be combined with other immune checkpoint receptor blockers to further enhance the anti-tumor effect. This evidence concerns the gene HAVCR2 and neoplasm.